Amlodipine is commonly used in the therapeutic domains of cardiovascular medicine, playing a role in managing several conditions characterized by periods of heightened symptoms related to heart and vascular function.

This medication is primarily used to address high blood pressure (hypertension), certain types of angina (chest pain), and coronary artery disease.

This treatment helps address symptoms related to systemic imbalance, which in turn assists with maintaining functional stability by lowering physiological stress. For discomfort related to coronary issues, it contributes to easing the overall symptom burden by reducing strain on the heart muscle. These effects are relevant in clinical settings that involve acute or unstable symptom patterns, providing supportive relief when symptoms create noticeable physiological strain.

Quick Fact: Relief for symptoms related to physical discomfort

“It provides support that helps ease the overall symptom burden during periods of heightened symptoms.”

Regulatory References

1. NIH MedlinePlus Drug Information

Amlodipin Stada (amlodipine) is generally allowed for use in adults and children aged 6 to 17 years for the treatment of hypertension, but only for adults when treating angina.

Populations for Whom Use is Prohibited (Contraindicated)

Official regulatory sources strictly prohibit the use of this medicine in patients with:

• Hypersensitivity or allergy to amlodipine, other dihydropyridine derivatives, or any of the excipients.
• Severe hypotension (very low blood pressure).
• Shock, including cardiogenic shock.
• Obstruction of the outflow tract of the left ventricle (e.g., high-grade aortic stenosis).
• Haemodynamically unstable heart failure after an acute myocardial infarction.
• Women who are breast-feeding (due to the excretion of amlodipine into human milk).

Groups Requiring Special Consideration

Use requires caution or special monitoring for several patient groups:

Population / Condition	Eligibility Status / Restriction
Children under 6 years	Use not established; safety and efficacy are not documented.
Severe Hepatic Impairment	Use with caution; treatment should be initiated at the lowest dose and titrated slowly.
Elderly Patients	Use with caution; normal dosage is recommended, but increasing the dosage should be done carefully.
Renal Impairment	Generally allowed; normal dosage is typically recommended as renal impairment does not significantly alter amlodipine clearance.

Pregnant women should only use this medicine when there is no safer alternative, and the benefits clearly justify the potential risk, as safety has not been established in human pregnancy.

The official regulatory profile for Amlodipin Stada interactions is defined by its metabolic pathway and pharmacodynamic properties. No medicinal product combinations are formally classified as strictly contraindicated in the core prescribing information.

Pharmacokinetic and Metabolic Interactions

The primary pharmacokinetic interaction is linked to the CYP3A4 enzyme system. Co-administration with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) is documented to increase the systemic exposure to Amlodipine, affecting its plasma concentration area under the curve (AUC). Conversely, strong CYP3A4 inducers (e.g., rifampicin, St John's Wort) may reduce the plasma concentration of the medicine.

A specific interaction with Simvastatin results in increased systemic exposure to the statin, leading to an officially documented upper daily dose restriction for Simvastatin when co-administered with Amlodipin Stada.

Pharmacodynamic and Dietary Interactions

Amlodipin Stada, when co-administered with other antihypertensive agents, can result in an additive blood pressure lowering effect. This effect is a common pharmacodynamic interaction documented in the medicine's regulatory label.

Interaction Type	Interacting Substance Example	Official Outcome
Dietary	Grapefruit or Grapefruit Juice	May increase Amlodipine systemic exposure.
Herbal	St John's Wort	May reduce Amlodipine plasma concentration.

Population-Specific Consideration

The regulatory label indicates that the increase in Amlodipine exposure observed with CYP3A4 inhibitors is more pronounced in both elderly patients and those with hepatic impairment.

Amlodipine's mechanism involves modulation of the vascular smooth muscle tone via interference with calcium-dependent signaling pathways. The drug's mechanism results in the physiological consequence of arterial smooth muscle relaxation and a reduction in the force required to expel blood from the heart (afterload).

Modulating Calcium-Dependent Smooth Muscle Contraction

Amlodipine acts as a slow-channel blocker of the L-type voltage-dependent calcium channels found predominantly in peripheral arterial smooth muscle cells. By inhibiting the influx of extracellular calcium ions (Ca^2+), the drug interrupts the fundamental excitation-contraction coupling cascade that mediates muscle contraction.

Reducing Systemic Vascular Resistance

This domain addresses the mechanistic cascade and resulting systemic physiological consequences. The resulting widespread relaxation of the arterial smooth muscle causes extensive peripheral arterial vasodilation (widening). This widening reduces the frictional resistance to blood flow, resulting in a decrease in the Systemic Peripheral Vascular Resistance (PVR) and a subsequent decrease in the cardiac afterload.

How to Use Amlodipin Stada

Amlodipin Stada is an oral tablet intended for long-term administration and must be taken by mouth once daily. The official dosing regimen is structured to ensure continuous presence of the active substance, Amlodipine, in the circulatory system. The medicine may be taken with or without food, offering flexibility in its daily timing. To maintain a stable concentration, it is important to administer the dose at approximately the same time each day.

---

Official Dosing Regimens

The standard adult treatment typically begins with an initial starting dose of 5 mg once daily. The maximum allowed daily dose for adults across all approved indications is 10 mg. Dose adjustments, if required, are performed gradually and should not occur frequently, as the medicine takes at least 7 to 8 days to achieve stable plasma levels following a change.

---

Administration for Specific Populations

In certain patient groups, a lower initial dose may be applied. Older adults may be started on a reduced dose of 2.5 mg once daily. Similarly, for patients with hepatic impairment, the lowest starting dose (2.5 mg or 5 mg) is recommended. For pediatric patients aged 6 to 17 years being treated for hypertension, the starting dose is 2.5 mg once daily, with a maximum of 5 mg once daily. Patients with renal impairment typically do not require dose adjustment.

---

Handling Instructions

If a dose is missed, the standard approach is to skip the missed dose and resume the normal schedule the following day; it is explicitly stated that two doses should not be taken at once to compensate. The tablets are typically swallowed whole, but may be dispersed in water for immediate consumption if necessary.

Amlodipin Stada: Recent Clinical Evidence

Evidence for use in High Blood Pressure (Hypertension)

Research into Amlodipin Stada for high blood pressure was studied for both short-term stabilization and longer-term outcomes. The evidence landscape primarily consists of large-scale Randomized Controlled Trials (RCTs) and systematic meta-analyses that combine data from multiple studies. These trials research examined how blood pressure levels changed over defined time intervals. Longer-term evidence research describes how blood pressure measures evolved in the observed populations over follow-up periods that could last several years. Furthermore, studies monitored the incidence of serious cardiovascular events, such as stroke and myocardial infarction.

However, the existing research also contains areas of uncertainty. Analysis of combined data indicates patterns where a different incidence of outcomes, such as hospitalization for heart failure, was observed in some studies when Amlodipine was compared to certain other types of high blood pressure medications. Comparative evidence against all available drug classes is not equally extensive, which limits direct long-term comparisons across all therapeutic options.

Evidence for use in Coronary Artery Disease and Angina

Amlodipin Stada research examined patients with conditions associated with acute or disruptive episodes, specifically chronic stable angina and coronary artery disease (CAD). Randomized Controlled Trials and sub-studies from larger outcome trials were observed in patients with documented coronary artery disease. The studies research examined outcomes related to angina symptoms, focusing on patient-reported outcomes describing perceived discomfort. Researchers monitored change in the frequency of angina symptoms and the need for coronary revascularization procedures. Findings describe patterns observed in the studies regarding the evolution of these symptomatic and procedural outcomes during the defined study periods.

Long-term Follow-up and Durability of Evidence

The available evidence was observed in studies over various timeframes. For serious cardiovascular endpoints, the research included trials with extended follow-up durations. These studies tracked outcomes systematically for periods of up to multiple years. Research describes the long-term patterns observed in these large patient groups. However, the exact long-term effects for all possible outcomes are not fully established, as follow-up durations were limited in some of the specific comparator and angina studies.

Research in Special Patient Populations

Research was evaluated in specific patient groups that experience conditions involving periods of heightened symptoms. Studies research examined outcomes in older adults with high blood pressure and angina. There is limited information available for certain subgroups, but research has explored its use in patient populations with co-existing conditions, such as diabetes and chronic kidney disease. Overall, the results apply only to the populations studied, and data for certain groups remain insufficient when compared to the evidence base for the general adult population.

Evidence Gaps and Areas of Uncertainty

This summary highlights what is known—and what is still uncertain—about the evidence for Amlodipin Stada. Specifically, findings were mixed from research that was evaluated in patients with severe, chronic heart failure; therefore, the certainty remains low regarding outcomes in that population. Furthermore, comparative evidence is lacking in some subgroups of patients with coronary artery disease where concurrent high blood pressure was not present. This indicates that while the evidence landscape is broad, the data for certain groups remain insufficient or heterogeneous across the full spectrum of possible clinical situations.

Key Studies & References

1. Impact of amlodipine on clinical outcomes for heart failure in patients with dilated cardiomyopathy: a Korean nationwide cohort study (Discussing the PRAISE trial inconsistency)
2. Amlodipine in the Treatment of Patients with Stable Angina Pectoris
3. Amlodipine in elderly hypertensive patients: Pharmacokinetics and pharmacodynamics (Special Populations: Elderly)
4. Amlodipine - StatPearls - NCBI Bookshelf (Review of FDA Indications and Special Populations)

Common questions about Amlodipin Stada (FAQ)

Q: How long does it usually take to see a change in blood pressure after starting this medicine?

A: After taking a single dose, the concentration of the medication in the bloodstream typically peaks within 6 to 12 hours. Regulatory information notes that the body reaches stable, steady-state levels of the medicine after approximately 7 to 8 days of taking the daily dose. This consistent concentration is foundational for the medicine's full effect.

Q: What should I do if I accidentally forget to take Amlodipin Stada?

A: If a dose is missed, official instructions advise taking it as soon as it is remembered that day. If an entire day is forgotten, the missed dose should be skipped entirely, and the dose should not be doubled to compensate. The regular daily schedule should be resumed the following day.

Q: Does eating grapefruit affect how Amlodipin Stada works?

A: Official documents state that consuming grapefruit or grapefruit juice may increase the amount of Amlodipine that enters the body. This increased exposure may raise the risk of experiencing side effects, such as low blood pressure. Official guidance notes that this combination should be used with caution.

Q: Can Amlodipin Stada affect blood sugar levels in people with diabetes?

A: Clinical studies have examined the use of Amlodipine in patients who also have diabetes. Research indicates that this medication can be used to control blood pressure in this population. The trials reviewed did not report a significant negative impact on blood sugar control or kidney function.

Q: How does Amlodipin Stada affect people who drive or operate machinery?

A: The official safety profile lists side effects such as dizziness, headache, and fatigue. If these effects occur—especially when treatment is initiated or a dose is adjusted—they may affect the ability to safely drive or operate machinery. Awareness of these possible effects is necessary.

Q: Do the side effects of Amlodipin Stada go away over time?

A: Regulatory safety information notes that certain effects, such as dizziness and somnolence (sleepiness), are described as potentially more frequent at the start of treatment. Official information indicates that the frequency of these specific effects may decrease after the body has adjusted to the medication.

Q: Why might a doctor switch me from another blood pressure medicine to Amlodipin Stada?

A: Amlodipine is described in regulatory documents as a first-line treatment for high blood pressure and angina. Amlodipine's use is supported by large-scale randomized controlled trials. It may be chosen alone or in combination with other agents to help achieve specific blood pressure goals.

Q: How is Amlodipin Stada different from other medications for high blood pressure?

A: Amlodipine is classified as a dihydropyridine Calcium Channel Blocker (CCB). This class works by inhibiting the movement of calcium ions into vascular smooth muscle, causing the arteries to relax and widen (vasodilation). This action differs from how other major drug classes, such as ACE inhibitors or beta-blockers, function.

Q: Does Amlodipin Stada thin the blood?

A: Amlodipin Stada is a Calcium Channel Blocker (CCB) that works to relax blood vessels. It is not classified as an anticoagulant (blood thinner). Its action is focused on relaxing the blood vessels (vasodilation), not on altering blood clotting or platelet function.

Q: Can Amlodipin Stada be used for anxiety or stress-related high blood pressure?

A: Official regulatory documents define the indications for this medicine as the treatment of hypertension (high blood pressure) and chronic stable angina (chest pain). Anxiety or stress-related blood pressure is not listed as a formal indication.

Q: Is it normal to feel tired when first starting Amlodipin Stada?

A: Regulatory documents list fatigue and somnolence (sleepiness) as common side effects, meaning they may affect up to 1 in 10 people. These effects are also officially noted as being potentially more frequent when starting treatment.

Q: Are there any common supplements or vitamins that might interact with Amlodipin Stada?

A: Regulatory information explicitly lists the herbal supplement St John's Wort as a substance that may reduce the concentration of Amlodipine in the bloodstream. While other supplements are not individually listed, caution is generally recommended due to the potential for unknown effects on how the body processes the medicine.

Q: What are the restrictions on alcohol consumption while using Amlodipin Stada?

A: Since alcohol can lower blood pressure, combining it with this medicine may increase the risk of hypotensive effects, such as dizziness or lightheadedness. This risk is particularly relevant when treatment is initiated.

Q: Is Amlodipin Stada a diuretic (water pill)?

A: No, Amlodipin Stada is not classified as a diuretic, or 'water pill.' It belongs to the class of Calcium Channel Blockers. Its primary function is to relax blood vessels, which is distinct from diuretics that work by increasing salt and water excretion via the kidneys.

Q: What does the research say about Amlodipin Stada use in children?

A: Research supports the use of this medicine for treating high blood pressure in pediatric patients aged 6 to 17 years. Clinical trials established the appropriate dosing range for this age group, but doses higher than 5 mg daily have not been studied in this population.

Q: Are there any known issues with taking Amlodipin Stada before having surgery?

A: Because Amlodipine reduces blood pressure, this effect may be magnified during general anesthesia or surgical procedures. The official label notes that a patient’s care team should be informed that they are taking this medication before any planned surgery.

Q: Is hair loss listed as a possible side effect of Amlodipin Stada?

A: Some regulatory documents list hair loss (alopecia) as an uncommon side effect, affecting up to 1 in 100 people. Reports of hair loss are also included in post-marketing surveillance information.

Q: Can Amlodipin Stada cause weight gain or weight loss?

A: Regulatory documents include reports of both weight gain and weight loss from post-marketing surveillance. The weight gain reported may also be associated with fluid retention, as peripheral edema (swelling) is a common side effect of Amlodipine.

Q: Is Amlodipin Stada considered a beta-blocker?

A: No, Amlodipin Stada is classified as a Calcium Channel Blocker (CCB). It belongs to a different pharmacological class than beta-blockers, which act by blocking the effects of epinephrine (adrenaline) to slow the heart rate.

Q: Does Amlodipin Stada cause heart palpitations or a change in heart rate?

A: Yes, palpitations (a sensation of a pounding heart) are listed in official documents as a common side effect, affecting up to 1 in 10 people. More serious changes in heart rhythm (arrhythmia) are classified as a very rare side effect.

Q: What happens if Amlodipin Stada is taken with cold or flu medicines?

A: Some over-the-counter cold or flu medicines contain ingredients that can raise blood pressure or potentially interact with Amlodipine’s metabolism. Due to potential interactions, regulatory guidance recommends that a healthcare professional be consulted before beginning any over-the-counter cold or flu treatment.

Q: Is there research evidence suggesting Amlodipin Stada is helpful for certain types of headaches?

A: The official indications for Amlodipine are strictly for high blood pressure and chronic stable angina. While certain calcium channel blockers have been studied for headache conditions, the official research evidence for Amlodipine is not focused on specific headache treatment.

Q: Does taking Amlodipin Stada affect lab test results like cholesterol?

A: Clinical trials examining Amlodipine in patients with high blood pressure and other conditions have shown that it effectively lowers blood pressure. These studies did not report a significant negative impact on blood lipid (cholesterol) levels or blood sugar (glycemic) parameters.

Q: Can Amlodipin Stada cause muscle aches or joint pain?

A: Yes, regulatory safety documents list muscle cramps and arthralgia (joint pain) as uncommon side effects, meaning they may affect up to 1 in 100 people. Myalgia (muscle pain) is also listed as a common or uncommon side effect.

Q: Do studies show Amlodipin Stada is less effective in certain racial groups?

A: Clinical trial reports include patient demographic information, including race and ethnicity. Differences in response to antihypertensive agents have been a subject of research, but official regulatory labels do not make claims of reduced efficacy in any specific racial group for the approved uses.

Q: Are there any known interactions between Amlodipin Stada and herbal teas?

A: Regulatory information explicitly lists the herbal product St John’s Wort as a substance that may reduce the concentration of Amlodipine in the bloodstream. Other herbal teas are not specifically listed but may carry a risk due to potential unknown effects on the body's drug processing enzymes.

Q: How often do the serious side effects of Amlodipin Stada typically occur?

A: Serious adverse reactions, such as severe heart problems (myocardial infarction, arrhythmia) or inflammation of organs (hepatitis, pancreatitis), are classified as Very Rare in regulatory documents. This classification means they may affect less than 1 in 10,000 patients.

Q: Can taking Amlodipin Stada cause issues with gum health?

A: Official safety information lists gingival hyperplasia (gum enlargement) as a very rare side effect. This classification means it may affect less than 1 in 10,000 patients.

Q: Does the time of day I take Amlodipin Stada matter for its effectiveness?

A: The medicine is designed to be effective for a full 24 hours when taken once daily. While it is generally recommended to take it at the same time each day for treatment consistency, the medication's gradual and long-lasting action means the specific time of day does not significantly alter its overall daily effectiveness.

Q: Are there common signs that Amlodipin Stada might not be working for someone?

A: Amlodipine is prescribed to manage blood pressure or angina. Indications that the medicine may not be providing the expected therapeutic benefit would include sustained high blood pressure readings or a lack of improvement, or worsening, in angina symptoms.

Q: Is Amlodipin Stada available as a liquid or chewable form?

A: Official documentation lists Amlodipine as being available in oral tablet form. Various formulations of the active ingredient Amlodipine, such as liquid suspension or powder for solution, may be available under different trade names.

Q: What happens if I stop taking Amlodipin Stada suddenly?

A: Official labels generally caution against abruptly stopping calcium channel blocker therapy, particularly for patients with coronary artery disease. Sudden discontinuation may be associated with an increase in the frequency or severity of angina symptoms in some patients. Therefore, abrupt cessation is generally cautioned against in official labels.

How to Store and Dispose of Amlodipine Tablets

The storage and disposal instructions for amlodipine tablets are established by regulatory agencies to maintain the product's integrity and ensure safety.

Official Storage Requirements

Amlodipine tablets must be stored at Controlled Room Temperature, which is generally defined as 15 C to 30 C (59 F to 86 F). The medicine must be kept in the original container, tightly closed, and stored in a dry place away from moisture and direct light. Do not store the medicine in a bathroom. All medication must be kept strictly out of sight and reach of children.

Disposal Instructions

The most recommended method for discarding unused or expired amlodipine is through an official drug take-back program. If this option is unavailable, the medication can be mixed with an undesirable substance, such as dirt or used coffee grounds, sealed in a bag or container, and placed in the household trash. Amlodipine is not on the government's list of medicines recommended for flushing down the toilet.